Phoenix Wealth Advisors’s Intellia Therapeutics NTLA Stock Holding History

Phoenix Wealth Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,755	Closed	-$235K	–	111
2023 Q2	$235K	Sell	5,755 -274	-5%	-$11.1K	0.14%	99
2023 Q1	$225K	Sell	6,029 -33	-0.5%	-$1.29K	0.14%	98
2022 Q4	$212K	Sell	6,062 -855	-12%	-$40.7K	0.13%	105
2022 Q3	$387K	Sell	6,917 -419	-6%	-$26K	0.39%	55
2022 Q2	$380K	Sell	7,336 -929	-11%	-$47.2K	0.37%	60
2022 Q1	$558K	Buy	8,265 +3,949	+91%	+$335K	0.58%	41
2021 Q4	$510K	Sell	4,316 -439	-9%	-$55K	0.39%	62
2021 Q3	$638K	Buy	4,755 +163	+4%	+$24.7K	0.48%	56
2021 Q2	$686K	Sell	4,592 -3,664	-44%	-$285K	0.49%	58
2021 Q1	$661K	Sell	8,256 -2,477	-23%	-$166K	0.51%	47
2020 Q4	$584K	Buy	+10,733	New	+$390K	0.44%	52

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Phoenix Wealth Advisors's NTLA Position: Q3 2023 in Review

Phoenix Wealth Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 5,755 shares — an estimated $235K sold.

Phoenix Wealth Advisors first reported a position in NTLA in Q4 2020 and held it in 11 quarters. The position peaked at $686K in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

Phoenix Wealth Advisors reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
Phoenix Wealth Advisors sold 5,755 Intellia Therapeutics shares in Q3 2023, an estimated $235K.
Phoenix Wealth Advisors first reported a position in Intellia Therapeutics in Q4 2020 and held it in 11 quarters.
Phoenix Wealth Advisors's Intellia Therapeutics position peaked at $686K in Q2 2021.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Phoenix Wealth Advisors's 13F filing for Q3 2023, filed 6 Nov 2023.